DUBLIN GE Healthcare Life Sciences' $150 million investment in the creation of GE Biopark Cork, which it unveiled this week, is its first foray into building a prefabricated, off-the-shelf biomanufacturing facility that will cater to multiple tenants. It provided delegates at a pre-conference session on biomanufacturing, held as part of the Biopharma Ambition 2016 meeting in Dublin, with a tangible glimpse of the future of biologics drug production.
The company has completed the rollout of two of its Kubio facilities, both in China, for JHL Biotech Inc., of Zhubei, Taiwan, and for New York-based Pfizer Inc. But it has chosen Ireland as the location for its first initiative that will involve several customers in a single site. It represents a further evolution of the business it has built around its 2012 acquisition of Marlborough, Mass.-based Xcellerx Inc., a developer of turnkey and single-use biomanufacturing systems.